Introduction {#S1}
============

The development of behavioral addictions (BAs, also referred to as impulse control disorders) in association with dopamine agonists (DAs, commonly used to treat Parkinson's disease) has been reported ([@B3]; [@B4]; [@B10]; [@B12]). [@B8] present evidence that these reported associations are evident in the US Food & Drug Administration's (FDA) Adverse Event Reporting System (FAERS), a database containing information on adverse drug event (ADE) and medication error reports submitted to the FDA. Specifically, [@B8] conducted a retrospective disproportionality analysis based on the 2.7 million serious domestic and foreign ADEs reported to the FAERS from 2003 to 2012. A threshold consisting of a proportional reporting ratio (PRR) ≥ 2 was used to detect signals (drug-associated adverse events) involving any of six DAs and any of 10 terms (or ADEs) in the Medical Dictionary for Regulatory Activities characterized as BAs. They identified 1,580 reports containing at least one BA, 710 of which also contained a DA, and reported a PRR for reports containing both a BA and a DA (BAs w/DAs) of 277.6 (*p* \< 0.001).

The authors concluded that their findings confirm prior reports of a BA/DA association. However, given three factors, it is possible that their findings could have been affected by publicity. First, vulnerability to publicity-stimulated reporting has been described as a limitation of spontaneous reporting systems like the FAERS ([@B1]; [@B7]). Second, between 2003 and 2012, the development of BAs in association with DAs received considerable media coverage on multiple occasions. Third, a 2014 research report, which, in its analysis of FAERS reporting cast a wider net than [@B8] with respect to both number of BAs analyzed (16 versus 10) and type of report analyzed (both serious and non-serious reports were included), found no or only very weak associations prior to publicity between DAs and BAs that could be grouped under the general headings binge eating, compulsive shopping, and hypersexuality (pre-publicity data on reports of gambling to the FAERS are not freely available) ([@B6]).

[@B8] briefly allude to the issue of publicity in their discussion and suggest that it cannot account for their findings. Specifically, they characterize growth in BA w/DA reporting ("dopamine receptor agonists" in [Figure 1](#fig1){ref-type="fig"}) between 2003 and 2012 as steady and conclude that it is therefore unlikely that a burst of publicity or specific events explain their findings. We contend that growth in BA w/DA reporting between 2003 and 2012 was not steady, but rather it fluctuated, with upticks in reporting in 2004 (approximately 133%) and 2011 (approximately 49%), and a sustained period of growth between 2005 and 2009 (approximately 588%). Given the observations listed in the previous paragraph, we hypothesized that these fluctuations may coincide with publicity.

![Trend over time for reports of pathological gambling, hypersexuality, and related impulse control disorders.\
Total domestic and foreign reports of serious injury received by the US Food and Drug Administration containing any of 10 terms in the Medical Dictionary for Regulatory Activities that characterize the impulse control disorder under study. (Reproduced with permission from the American Medical Association: *JAMA Internal Medicine* ([@B8]; *174*(12):1930--1933.) Copyright © 2014 American Medical Association. All rights reserved.)\
*Note:* In the current study, impulse control disorders are referred to as behavioral addictions, or BAs](2006.5.2016.001_f001){#fig1}
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To investigate the possibility that these fluctuations may coincide with media coverage, we conducted Internet searches of 16 major US and international English-language media outlets between 2003 and 2012 for the keywords Parkinson's AND gambling. Of the 68 news stories identified using this strategy, 35 were included. News stories were excluded if they only briefly mentioned a BA/DA association (26 stories); keywords were found among "comments" on a story (four stories); they were in "question and answer" or "Dear Doctor" format (two stories); or the webpage or article was no longer accessible (one story).
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Results {#S3}
=======

Of the 35 included news stories, 15 were precipitated by scientific publications (43%); 10 by lawsuits (29%); 7 by conference presentations (20%); 1 by a change in pharmaceutical company advertising (3%); 1 by a patient's story (3%); and 1 for which the catalyst was unclear (3%).

Results are summarized in [Figure 2](#fig2){ref-type="fig"}. The uptick in BA w/DA reporting in 2004 seen in [Figure 1](#fig1){ref-type="fig"} follows a news story in the New York Times in August 2003 ([@B9]), precipitated by the publication in the same month of research conducted by [@B4]. The uptick in 2011 follows four news stories in January and February of 2011 triggered by lawsuits, as well as a CBS news story in June 2010 ([@B5]) precipitated by a scientific publication ([@B12]). The approximately 588% growth in BA w/DA reporting observed between 2005 and 2009 coincides with the publication of 26 news stories (74% of the 35 news stories included) between July 2005 and April 2009, most of which were prompted by scientific publications ([@B2]; [@B3]; [@B10]; [@B11]), conference presentations, and lawsuits.

![Number of news stories covering a BA/DA association, 2003--2012.\
BA = behavioral addiction, DA = dopamine agonist.\
*Note:* News stories data were compiled from Internet searches of 16 major US and international English-language media outlets for the terms Parkinson's AND gambling (ABC News, CBS News, CNBC, CNN, The Globe & Mail, The Guardian, Huffington Post, MSNBC, NBC News, The New York Times, NPR, Scientific American, Time, USA Today, The Wall Street Journal, and The Washington Post)](2006.5.2016.001_f002){#fig2}

Discussion {#S4}
==========

Upticks in BA w/DA reporting to the FAERS appear to either follow or coincide with publication of news stories. Moreover, fluctuations in BA w/DA reporting are not reflected in the trajectories plotted for all FAERS reports or BA w/non-DA reports ([Figure 3](#fig3){ref-type="fig"}), which suggests the presence of some influence on the BA w/DA reporting rate specifically. That fluctuations in news coverage may coincide with fluctuations in BA w/DA reporting suggests the possibility that publicity may have influenced reporting.

![Trend over time for BA w/non-DA and all FAERS reports, 2003--2012.\
FAERS = US Food & Drug Administration's (FDA) Adverse Event Reporting System, BA = behavioral addiction, DA = dopamine agonist.\
*Note:* BA w/non-DA reports data were estimated based on data presented in [@B8] (see [Figure 1](#fig1){ref-type="fig"}). All FAERS reports data were obtained from the FDA's website at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm083765.htm>](2006.5.2016.001_f003){#fig3}

Given the possibility that publicity could have influenced their findings, it would have been helpful if [@B8] had provided PRRs for clinically related groupings of the 10 BAs analyzed. This would make it easier to assess the degree to which the overall PRR of 277.6 may be driven by pathological gambling/gambling (two separate ADEs in the FAERS), which, in 2003, was the first BA to be reported in association with DAs in the mainstream media. Pathological gambling/gambling was also the BA most frequently reported to the FAERS between 2003 and 2012, accounting for 42.7% of the 1,902 reports of BAs identified by [@B8]. It would also have been interesting to see a comparison between the 2003 PRRs (pre-publicity for all but pathological gambling) and the 2012 PRRs (post-publicity for all BAs) for clinically related groupings of the 10 BAs analyzed.

It should be noted that significant complexities exist in identifying the specific factors that might cause ADEs and their reporting. While publicity may influence reporting, it is also possible that FAERS reporting may have led to increased publicity, perhaps indirectly through analysis and reporting of findings. Possible examples may include through the FDA's quarterly reporting of potential drug safety issues identified via analysis of FAERS data; updates to product labeling or product advertising resulting from analysis of FAERS reporting; or scientific publication of analysis of FAERS reporting. Of the 35 news stories included in the analysis, one cites as its catalyst an update to possible adverse events listed in a product's television advertisements, a change the product manufacturer says was prompted by a request from the FDA, and two stories cite as an impetus scientific publication of analysis of FAERS reporting. We also note the gradual nature of the sizable uptick in BA w/DA reporting between 2005 and 2009, which occurs in the midst of several years of increased media coverage of a BA/DA association. This finding would be consistent with a possible lag, with information taking time to circulate and lead to reporting, although other possibilities also exist. It is possible that the BA w/DA data presented in [Figure 1](#fig1){ref-type="fig"} are influenced by multiple factors, some of which are indicated above. While we do not cover an exhaustive list, the notion that reporting of BAs in association with DAs might be influenced by publicity has important clinical and public health implications, and is thus not a notion that should be prematurely dismissed.

Conclusions {#S5}
===========

In summary, a BA/DA association has received considerable publicity since it was first reported in 2003. Data suggest that publicity may stimulate ADE reporting, and in this case it may coincide with fluctuations in BA w/DA reporting. It is important to evaluate the potential effect of publicity on ADE reporting to guard against mistaking an increased risk of an ADE being reported for an increased risk of an ADE occurring ([@B7]).
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